Cystic fibrosis treatment combines daily therapies that keep the lungs clear, medications that target the underlying genetic defect, digestive support, and infection control. Most people with CF follow a multi-layered routine that touches nearly every part of the day, from morning airway clearance sessions to enzyme capsules taken with every meal. The good news: treatments have improved dramatically in the last decade, and a class of drugs called CFTR modulators now addresses the root cause of the disease for the majority of people with CF.
CFTR Modulators: Treating the Root Cause
Cystic fibrosis is caused by mutations in a gene that controls the flow of salt and water across cell surfaces. When that channel doesn’t work properly, mucus throughout the body becomes thick and sticky. CFTR modulators are oral medications that help the defective protein function more normally, and they represent the biggest shift in CF care in decades.
There are currently five approved CFTR modulators, each designed for specific genetic mutations:
- Alyftrek is one of the newest options, approved for people ages 6 and older who carry certain mutations, including 31 rare ones.
- Trikafta is approved for ages 2 and older with at least one copy of the F508del mutation (the most common CF mutation) or one of 271 other specified mutations. This covers a large majority of the CF population.
- Symdeko is approved for ages 6 and older with two copies of F508del or a single copy of one of 154 other mutations.
- Orkambi is approved for ages 1 and older with two copies of F508del.
- Kalydeco is approved from 1 month of age for people with one of 97 specified mutations.
Trikafta, in particular, has been transformative. In clinical trials, it produced significant improvements in lung function and reduced the frequency of serious lung flare-ups. For many people, starting a modulator means less mucus, easier breathing, fewer hospitalizations, and better weight gain. These drugs don’t cure CF, but they slow disease progression substantially and improve quality of life in ways that were not possible a generation ago. Not everyone qualifies, though. Eligibility depends entirely on which mutations you carry, which is determined through genetic testing.
Airway Clearance Techniques
Even with modulator therapy, keeping the lungs clear of thick mucus remains a cornerstone of CF care. Most people with CF perform airway clearance at least once or twice a day, and more often during illness. The goal is to loosen mucus from the walls of the airways and move it up where it can be coughed out. Several methods exist, and the right choice depends on age, lung function, and personal preference.
Oscillatory PEP devices are among the most popular tools. Handheld devices like the Aerobika, Acapella, and Flutter create vibrations and back-pressure as you exhale through them, helping to shake mucus loose from airway walls. Sessions typically last 10 to 15 minutes, once or twice a day. They’re portable, relatively inexpensive, and easy to use independently, which makes them a practical choice for school, work, or travel.
Percussion vests (sometimes called high-frequency chest wall oscillation) are inflatable vests connected to a machine that rapidly vibrates the chest. Sessions last about 20 minutes and can be done multiple times a day. The vest does most of the work, which makes it a good option for people who have difficulty with active breathing techniques, though it’s more expensive and less portable.
The Active Cycle of Breathing Technique requires no equipment at all. It involves a specific sequence of relaxed breathing, deep breaths to expand the lungs, and forced exhalation (huffing) to push mucus upward. Sessions typically take about 20 minutes, two to three times per day. Many people prefer it because it can be done anywhere without special tools.
Managing Lung Infections
Thick mucus creates a breeding ground for bacteria, and chronic lung infections are one of the most serious complications of CF. Pseudomonas aeruginosa is the most concerning bacterium, and once it establishes a permanent presence in the lungs, the treatment focus shifts to suppressing it rather than eliminating it entirely.
Inhaled antibiotics are a mainstay of chronic infection management. Tobramycin and colistin are the two most widely used, delivered through a nebulizer directly into the lungs. Tobramycin is also available as an inhalable powder, which is faster to administer. These are often used on alternating cycles of 28 days on, 28 days off. Aztreonam lysine (marketed as Cayston) is a newer inhaled antibiotic that serves as an alternative for people who don’t tolerate or respond well to tobramycin.
During acute flare-ups, called pulmonary exacerbations, treatment typically involves more aggressive courses of antibiotics, often given intravenously over two to three weeks either in the hospital or at home. Sputum cultures, recommended at least quarterly, help CF care teams identify which bacteria are present and which antibiotics will be most effective. Annual screening for nontuberculous mycobacteria, a harder-to-treat group of organisms, is also standard practice.
Digestive Support and Nutrition
About 85% of people with CF have pancreatic insufficiency, meaning the pancreas can’t release enough digestive enzymes to break down food properly. Without treatment, fat and nutrients pass through unabsorbed, leading to poor growth, vitamin deficiencies, and greasy, foul-smelling stools.
Pancreatic enzyme replacement therapy corrects this. Capsules containing digestive enzymes are taken with every meal and snack. Dosing is individualized, generally calculated by body weight (500 to 2,500 enzyme units per kilogram per meal) or by the fat content of the food (500 to 4,000 units per gram of fat). There’s a daily ceiling of 10,000 units per kilogram of body weight to avoid complications. For infants, the recommendation is up to 5,000 units per breastfeed or per 100 to 120 mL of formula. Getting the dose right is part science, part trial and error, and it often needs adjusting as eating habits change.
Beyond enzymes, nutrition in CF is about getting enough calories, since the body works harder to breathe and fight infections. High-calorie, high-fat diets are encouraged, which is the opposite of typical dietary advice. Fat-soluble vitamins (A, D, E, and K) are poorly absorbed in CF, so daily supplementation is standard. Salt replacement also matters. People with CF lose unusually large amounts of salt in their sweat. The general recommendation is to eat salty foods liberally and salt meals generously. During exercise or hot weather, adding 1/8 teaspoon of salt to 12 ounces of a sports drink can help prevent depletion. Infants with CF need 1/8 teaspoon of salt daily until 6 months, then 1/4 teaspoon after that.
Exercise and Physical Activity
Regular exercise is considered part of CF treatment, not just a lifestyle bonus. Physical activity helps loosen mucus, improves lung capacity, builds bone density (which can be compromised in CF), and supports the higher calorie intake the body needs. Aerobic exercise, strength training, and activities that involve deep breathing are all beneficial.
The main precaution is hydration and salt replacement, since CF sweat is significantly saltier than normal. Planning extra fluids and salty snacks around workouts, especially in warm weather, helps prevent the cramping and fatigue that come with sodium loss.
When Lung Transplant Becomes an Option
For people whose lung function declines severely despite treatment, lung transplantation becomes a consideration. CF care teams are advised to begin discussing transplant with anyone whose FEV1 (a measure of how much air you can forcefully exhale in one second) drops below 50% of predicted values.
Formal referral to a transplant center is recommended when lung function reaches specific thresholds. For adults, that means an FEV1 below 30%, or below 40% with additional warning signs like rapid decline, frequent exacerbations requiring IV antibiotics (more than two per year), a BMI below 18, or complications like significant bleeding or a collapsed lung. For children, the thresholds are slightly different: referral is recommended at FEV1 below 40%, or below 50% with markers of worsening disease.
Other triggers for referral, regardless of FEV1, include being unable to walk 400 meters in six minutes, needing supplemental oxygen at rest or during activity, or having elevated carbon dioxide levels in the blood. Transplant isn’t a cure for CF (the disease still affects the rest of the body), but it can dramatically extend life and improve breathing when the lungs have reached a point where other treatments can no longer maintain function.
Putting It All Together
What makes CF treatment uniquely demanding is that most of these therapies happen simultaneously, every day. A typical routine might include morning airway clearance, nebulized medications, enzyme capsules at each meal, vitamin supplements, inhaled antibiotics on a monthly cycle, and a CFTR modulator taken daily. Quarterly clinic visits with sputum cultures, annual screenings, and periodic lung function testing keep the care team informed about what’s working and what needs adjusting. The treatment burden is real, but each layer of this regimen plays a distinct role in slowing disease progression and maintaining quality of life.